HOME >> BIOLOGY >> NEWS
Two national diabetes-related initiatives coordinated by MCG bioinformatics expert

A national effort to develop animal models to study the devastating complications of diabetes is being coordinated by a Medical College of Georgia bioinformatics expert.

Dr. Richard A. McIndoe, associate director of the MCG Center for Biotechnology and Genomic Medicine, has received a $15 million, five-year grant the largest ever received by MCG to continue operating the Coordinating and Bioinformatics Unit for the innovative National Institutes of Health project, Animal Models of Diabetic Complications Consortium.

He also will begin providing the same services for the Mouse Metabolic Phenotyping Centers, another NIH-funded consortium of centers offering expertise in sophisticated, expensive mouse testing to scientists nationwide for a variety of diseases including diabetes and its complications as well as obesity and related disorders.

The Animal Models of Diabetic Complications Consortium consists of 13 investigators from different institutions generating ideas for creating mouse models, a Mouse Generation and Husbandry Core to generate the mice and the Coordinating and Bioinformatics Unit to oversee consortium activities.

"The NIH recognized years ago that there were few good animal models that mimic the complications of diabetes," Dr. McIndoe says. Even the NOD mouse, a spontaneous model for type 1 diabetes, is inadequate, primarily because complications tend to come with age and mice have a relatively short lifespan, he says.

Complications include cardiovascular and kidney disease, diabetic retinopathy as well as damage to the nerves and bladder. "Diabetic cardiovascular disease is probably the biggest mortality risk for type 1 and 2 diabetes; somewhere around 60 to 70 percent of diabetic mortality can be associated with cardiovascular disease," Dr. McIndoe says.

Unfortunately, the high risk of model development impeded financial support until several years ago when NIH opted to commit funds to
'"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
26-Oct-2006


Page: 1 2 3 4

Related biology news :

1. Multinational research: protecting ecology means understanding people, too
2. National Ecological Observatory Network featured at ESA/SER Joint International Conference
3. American buffalo slaughter fueled by international trade
4. NCRR launches national network to connect investigators based at minority institutions
5. CRESIB coordinates an international consortium to fight malaria caused by Plasmodium vivax
6. 2 MSU professors spearhead international water project
7. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
8. 2nd International EuroFIR Congress
9. Nature surrenders flowery secrets to international team
10. U of MN will lead national research study on causes of bone cancer in children
11. Fibers are center stage at international conference

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: